Wednesday, 18 November 2026European Markets

BERGENBIO Stock Is 12% Up So Far On Tuesday

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(VIANEWS) - Shares of BERGENBIO (Oslo Børs Benchmark Index_GI: BGBIO.OL) jumped by a staggering 12.41% to kr0.09 at 11:24 EST on Tuesday, after two consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI is sliding 0.21% to kr1,199.10, after two successive sessions in a row of gains. This seems, up to now, a somewhat negative trend exchanging session today.

About BERGENBIO

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Earnings Per Share

As for profitability, BERGENBIO has a trailing twelve months EPS of kr-2.61.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BERGENBIO's stock is considered to be oversold (<=20).

More news about BERGENBIO (BGBIO.OL).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 11 Jul 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›